Corpus Intelligence IC Memo — PALOMAR MEDICAL CENTER ESCONDIDO 2026-04-26 07:45 UTC
IC Memo — PALOMAR MEDICAL CENTER ESCONDIDO
Investment Committee Memorandum | CA | 292 beds | Grade C | EBITDA uplift $46.4M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

PALOMAR MEDICAL CENTER ESCONDIDO

CCN 050115 | SAN DIEGO, CA | 292 beds | April 26, 2026
EBITDA BridgeData Room
C
Investability

1. Target Overview & Investment Thesis

PALOMAR MEDICAL CENTER ESCONDIDO is a 292-bed community hospital in SAN DIEGO, CA with $630.5M in net patient revenue and a 2.0% operating margin. The hospital serves a payer mix of 19.0% Medicare, 0.0% Medicaid, and 81.0% commercial.

Thesis: Undervalued. Our ML models identify $46.4M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from 2.0% to 9.4% (+736bps).

Net Revenue HCRIS$630.5M
Current EBITDA COMPUTED$12.6M
Operating Margin COMPUTED2.0%
Occupancy HCRIS85.6%
Revenue / Bed COMPUTED$2.2M
Net-to-Gross HCRIS16.1%
Distress Probability MLnan%

2. Market Context & Competitive Position

414
CA Hospitals
-4.9%
State Median Margin
178
Comparable Hospitals

CA has 414 Medicare-certified hospitals with a median operating margin of -4.9%. The target's margin of 2.0% places it above the state median. Among 178 size-comparable peers (146-584 beds), the median margin is -3.9%. The target performs in line with or above peers.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (146-584), prioritizing same-state peers. 178 hospitals in the comp set.

HospitalStateBedsRevenueMargin
PALOMAR MEDICAL CENTER ESCONDI (Target)CA292$630.5M2.0%
RONALD REAGAN UCLACA446$2.62B-6.8%
LUCILE PACKARD CHILDRENS HOSPICA394$2.39B-0.8%
UCI MEDICAL CENTERCA397$1.90B-2.5%
CITY OF HOPE NATIONAL MEDICAL CA217$1.83B-10.7%
RADY CHILDRENS HOSPITAL - SAN CA401$1.82B14.8%
HARBOR-UCLA MEDICAL CENTERCA369$1.54B-6.4%
HOAG MEMORIAL HOSPITAL PRESBYTCA512$1.37B-3.9%
SUTTER MEDICAL CENTER - SACRAMCA523$1.36B0.5%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $46.4M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$13.2M+210bp18mo
Cost to Collect4.5%2.5%$12.6M+200bp12mo
Denial Rate Reduction12.0%6.5%$12.5M+198bp12mo
A/R Days Reduction5200.0%3800.0%$7.7M+122bp9mo
Clean Claim Rate88.0%96.0%$404K+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$13.2M
Cost to Collect
$12.6M
Denial Rate Reduction
$12.5M
A/R Days Reduction
$7.7M
Clean Claim Rate
$404K
Total EBITDA Uplift$46.4M
Current EBITDA$12.6M
+ RCM Uplift+$46.4M
Pro Forma EBITDA$59.0M
Current Margin2.0%
Pro Forma Margin9.4%
WC Released (1x)$24.2M

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$19.3M$547.0M28.31x95.2%
Base (11x exit)10.0x11.0x$19.3M$607.9M31.46x99.3%
Bull Case9.0x11.0x$17.4M$767.4M44.13x113.3%
Bull (12x exit)9.0x12.0x$17.4M$842.3M48.43x117.3%
Bear Case11.0x10.0x$21.3M$308.6M14.52x70.8%
Bear (11x exit)11.0x11.0x$21.3M$346.4M16.30x74.8%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
LowLow net-to-gross ratioLarge contractual allowances suggest pricing discipline issues. Mitigant: payer renegotiation is an additional upside lever

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 178 hospitals with 146-584 beds
  • Same-state prioritization (n=179)
  • Comp margins: P25=-15.8% / P50=-3.9% / P75=4.4%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.